Neomorph Banks $100M Series B for Degrader Biotech Acceleration

The degrader-focused biotech closed $100 million Series B led by Deerfield to accelerate NEO-811 into Phase 1/2 renal cell carcinoma trials, with backing from Regeneron Ventures and Longwood Fund.